HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toye, A. A. Articles by Cox, R. D. Search for Related Content PubMed PubMed Citation Articles by Toye, A. A. Articles by Cox, R. D. Social Bookmarking                What's this?

A New Mouse Model of Type 2 Diabetes, Produced by N-Ethyl-Nitrosourea Mutagenesis, Is the Result of a Missense Mutation in the Glucokinase Gene

¹ MRC Mammalian Genetics Unit, Medical Research Council, Harwell, Oxfordshire, U.K
² GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Harlow, U.K
³ GlaxoSmithKline Pharmaceuticals, Research Triangle Park, North Carolina

Here we report the first cloned N-ethyl-nitrosourea (ENU)-derived mouse model of diabetes. GENA348 was identified through free-fed plasma glucose measurement, being more than 2 SDs above the population mean of a cohort of >1,201 male ENU mutant mice. The underlying gene was mapped to the maturity-onset diabetes of the young (MODY2) homology region of mouse chromosome 11 (logarithm of odds 6.0). Positional candidate gene analyses revealed an A to T transversion mutation in exon 9 of the glucokinase gene, resulting in an isoleucine to phenylalanine change at amino acid 366 (I366F). Heterozygous mutants have 67% of the enzyme activity of wild-type littermates (P < 0.0012). Homozygous mutants have less enzyme activity (14% of wild-type activity) and are even less glucose tolerant. The GENA348 allele is novel because no mouse or human diabetes studies have described a mutation in the corresponding amino acid position. It is also the first glucokinase missense mutation reported in mice and is homozygous viable, unlike the global knockout mutations. This work demonstrates that ENU mutagenesis screens can be used to generate models of complex phenotypes, such as type 2 diabetes, that are directly relevant to human disease.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Goldsworthy, A. Hugill, H. Freeman, E. Horner, K. Shimomura, D. Bogani, G. Pieles, V. Mijat, R. Arkell, S. Bhattacharya, et al. Role of the Transcription Factor Sox4 in Insulin Secretion and Impaired Glucose Tolerance Diabetes, August 1, 2008; 57(8): 2234 - 2244. [Abstract] [Full Text] [PDF]

				F. M. Matschinsky, M. A. Magnuson, D. Zelent, T. L. Jetton, N. Doliba, Y. Han, R. Taub, and J. Grimsby The Network of Glucokinase-Expressing Cells in Glucose Homeostasis and the Potential of Glucokinase Activators for Diabetes Therapy Diabetes, January 1, 2006; 55(1): 1 - 12. [Abstract] [Full Text] [PDF]